Literature DB >> 19854294

Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.

Jozien Helleman1, Maurice P H M Jansen, Curt Burger, Maria E L van der Burg, Els M J J Berns.   

Abstract

Epithelial ovarian cancer is the sixth most common cancer in women worldwide and the most important cause of death from gynaecological cancers in the Western world. Our explorative pathway analysis on seven published gene-sets associated with platinum resistance in ovarian cancer reveals TP53 and transforming growth factor beta as key genes. Furthermore, the extracellular matrix was associated with chemotherapy resistance in ovarian cancer as well as endocrine resistance in breast cancer. Pathway analysis again revealed transforming growth factor beta as a key gene regulating extracellular matrix gene expression. A model is presented based on literature linking transforming growth factor beta, extracellular matrix, integrin signalling, epithelial to mesenchymal transition and regulating microRNAs with a (bivalent) role in chemotherapy response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19854294     DOI: 10.1016/j.biocel.2009.10.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  23 in total

Review 1.  Extracellular matrix dynamics and fetal membrane rupture.

Authors:  Jerome F Strauss
Journal:  Reprod Sci       Date:  2012-01-19       Impact factor: 3.060

2.  Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.

Authors:  Nuno Bernardes; Sofia Abreu; Filomena A Carvalho; Fábio Fernandes; Nuno C Santos; Arsénio M Fialho
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

Review 3.  Vitamin D and microRNAs in bone.

Authors:  Thomas S Lisse; John S Adams; Martin Hewison
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2013       Impact factor: 1.807

4.  Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Authors:  Laura D Hover; Christian D Young; Neil E Bhola; Andrew J Wilson; Dineo Khabele; Charles C Hong; Harold L Moses; Philip Owens
Journal:  Cancer Lett       Date:  2015-07-30       Impact factor: 8.679

5.  Effects Of Adenosine On Apoptosis Of Ovarian Cancer A2780 Cells Via ROS And Caspase Pathways.

Authors:  Bing Xia; Jing Wang
Journal:  Onco Targets Ther       Date:  2019-11-08       Impact factor: 4.147

6.  TRA-1-60+, SSEA-4+, Oct4A+, Nanog+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Ovaries.

Authors:  Marek Malecki; Mark Anderson; Michael Beauchaine; Songwon Seo; Xenia Tombokan; Raf Malecki
Journal:  J Stem Cell Res Ther       Date:  2012-11-18

7.  MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples.

Authors:  Xiao Li; Yaer Lu; Yaxia Chen; Weiguo Lu; Xing Xie
Journal:  BMC Cancer       Date:  2013-04-30       Impact factor: 4.430

Review 8.  Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.

Authors:  Alia Ghoneum; Sameh Almousa; Bailey Warren; Ammar Yasser Abdulfattah; Junjun Shu; Hebatullah Abouelfadl; Daniela Gonzalez; Christopher Livingston; Neveen Said
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 15.707

9.  MiR-200c and HuR in ovarian cancer.

Authors:  Silvia Prislei; Enrica Martinelli; Marisa Mariani; Giuseppina Raspaglio; Steven Sieber; Gabriella Ferrandina; Shohreh Shahabi; Giovanni Scambia; Cristiano Ferlini
Journal:  BMC Cancer       Date:  2013-02-08       Impact factor: 4.430

10.  Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.

Authors:  Xiao Li; Qianqian Pan; Xiaoyun Wan; Yuyan Mao; Weiguo Lu; Xing Xie; Xiaodong Cheng
Journal:  BMC Cancer       Date:  2015-07-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.